AbbVie

News

Data backs GSK's ovarian cancer blockbuster hopes

GSK's B7-H4-targeting ADC Mo-Rez chalks up impressive results in ovarian and endometrial cancer, prompting a major phase 3 trials programme.

News

US court says pharma giants must face False Claims suit

An appeals court in the US has said AbbVie, AstraZeneca, Novartis, and Sanofi must defend claims they defrauded federal and state governments.

News

FDA clears first all-oral combo for first-line CLL treatment

AstraZeneca's Calquence and AbbVie/Roche's Venclexta have become the first all-oral, fixed-duration regimen for newly-diagnosed CLL.

News

Tenpoint eyes presbyopia drug launch after FDA nod

Tenpoint is set to join the US market for drugs to treat presbyopia, taking on rival therapies from AbbVie, Orasis, and LENZ with a dual-acting rival.

News

CMS's Medicare price negotiations start round three

The US federal government has named the next 15 big-selling medicines that will be subject to Medicare pricing negotiations.

News

AbbVie turbocharges its US investment promise to $100bn

AbbVie finally agrees a Most-Favoured Nation pricing deal with the US administration, with a $100 billion investment promise attached.

Data backs GSK's ovarian cancer blockbuster hopes

US court says pharma giants must face False Claims suit

FDA clears first all-oral combo for first-line CLL treatment

Tenpoint eyes presbyopia drug launch after FDA nod

CMS's Medicare price negotiations start round three

AbbVie turbocharges its US investment promise to $100bn

Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer

Discover a new era of healthcare panel engagement: Grounded ...

AbbVie

Editor's Picks